

Proposed Project Scope

Nab-paclitaxel (in combination with Gemcitabine) for Previously Treated Advanced Pancreatic Cancer

Date: December 20, 2023

Background and Rationale

CADTH received a request from public drug programs for a Non-Sponsored Reimbursement Review of nab-paclitaxel in combination with gemcitabine for previously treated advanced pancreatic cancer.

Table I: Policy Questions

Item	Policy Question
1	Should nab-paclitaxel (in combination with gemcitabine) be publicly reimbursed for previously treated advanced pancreatic cancer?

Table II: Products Available in Canada

Product	Manufacturer
Nab-paclitaxel	n/a (generic)
Gemcitabine	n/a (generic)

Project Description

Table III: Project Scope

Criteria	Description
Population	Patients with previously treated advanced (locally advanced unresectable or metastatic) pancreatic cancer
Intervention(s)	Nab-paclitaxel and gemcitabine
Comparators	Single agent gemcitabine
Outcomes	Objective response rate (ORR), disease control rate (DCR), any grade 3 or 4 toxicity rate, specific grade 3 or 4 toxicity, progression-free survival, and overall survival.

Table IV: Research Questions

Item	Policy Question
1	What is the effectiveness of nab-paclitaxel (in combination with gemcitabine) for patients with previously treated advanced pancreatic cancer?
2	What are the harms associated with nab-paclitaxel (in combination with gemcitabine) for patients with previously treated advanced pancreatic cancer?
3	What is the expected cost of nab-paclitaxel (in combination with gemcitabine) vs. other reimbursed regimes for patients with previously treated advanced pancreatic cancer?

Key Project and Protocol Components

This project will follow the [Procedures for Non-Sponsored Reimbursement Reviews](#).

Status of the Document

This proposed project scope is being posted for information.